Sanofi sees higher earnings as blockbuster skin drug soars

In 2021, blockbuster eczema treatment Dupixent was the main growth driver for French Sanofi, and the company forecasts a bright 2022 for the drug.


Sanofi forecast double-digit profit growth for 2022 as blockbuster therapy Dupixent extends its reach in the US and Europe.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs